Search
Syndax Pharmaceuticals Inc
SNDXAdd to Watchlist
9.690USD
+0.320+3.42%
Market hours 11/06, 12:17（ET）
865.32MMarket Cap
LossP/E TTM
Today
+3.42%
5 Days
-31.52%
1 Month
-45.65%
6 Months
-51.79%
Year to Date
-53.88%
1 Year
-35.83%
Key Figures
9.515Open
10.490High
196.90KVolume
LossP/E TTM
LossP/E Dynamic
--Dividend TTM
0.22%Turnover Ratio
9.370Prev. Close
9.230Low
1.89MTurnover
LossP/E Static
-50.37P/B
0.00%Div Yield TTM
-43.70%ROA
25.59052wk High
0.07Volume Ratio
-318.76MNet Profit
89.30MShares
-2.7938EPS TTM
0.39Beta
-189.53%ROE
9.23052wk Low
13.45%Amplitude
83.20%Gross Margin
865.32MMarket Cap
-3.32Reward/Risk
3.73%Risk Rate
Syndax Pharmaceuticals Inc's Score
-0.30vs previous score
Forecast8.83
Financial Health6.16
Technical5.70
Valuation Dimensions7.23
Institutional Confidence10.00
Risk Assessment5.09
Media Coverage
Coverage Level
Very Low
Very High
Neutral
Analyst Rating
Syndax Pharmaceuticals Inc Technical Analysis
Technical Indicators
Strong sell
Summary
Sell
Moving Average
Strong sell
Syndax Pharmaceuticals Inc Latest Earnings Call Transcripts
Syndax Pharmaceuticals (SNDX) Q3 2026 Earnings Call: Revenue Rises 82% on Revuforj Growth
Syndax Pharmaceuticals Q3 2026 earnings call: revenue rose 82% to $83.3 million as Revuforj grew, while quarter-end cash reached $551 million.
Financial Indicators
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
Earnings
Next reporting date
--
Reporting Period
2026Q3
Earnings / Forecast
-0.55/-0.49
Revenue / Forecast
83.30M/81.85M
Syndax Pharmaceuticals Inc Profile
SectorBiotechnology & Medical Research
Ticker SymbolSNDX
Number of employees270
CountryUnited States of America
Ownership
| Shareholders | Proportion |
|---|---|
| Kynam Capital Management LP | 9.09% |
| BlackRock Institutional Trust Company, N.A. | 7.53% |
| Goldman Sachs & Company, Inc. | 6.13% |
| Point72 Asset Management, L.P. | 5.51% |
| Shareholder Types | Proportion |
|---|---|
| Hedge Fund | 40.28% |
| Investment Advisor | 37.84% |
| Investment Advisor/Hedge Fund | 22.19% |
| Research Firm | 12.69% |
Related Instruments
+0.01%
+0.46%
+0.36%
-0.14%
+0.45%
-0.21%
+0.09%
+0.16%
+0.16%
-0.58%
+0.86%
-0.73%
-0.57%
-0.12%
+8.96%
+0.24%
+0.33%
-0.87%
+0.98%
+2.90%Popular Instruments
51544.200
+45.100 (+0.09%)
27101.100
+465.900 (+1.75%)
7412.500
+55.600 (+0.76%)
12797.000
-1.000 (-0.01%)
58458.000
+1192.000 (+2.08%)
6155.300
-22.500 (-0.36%)
89.517
-0.516 (-0.57%)
343.640
-0.530 (-0.15%)
187.955
+6.355 (+3.50%)
4059.960
-38.730 (-0.94%)
FAQs
What is the current price of Syndax Pharmaceuticals Inc (SNDX)?
The current price of Syndax Pharmaceuticals Inc (SNDX) is 9.37.
What is the symbol of Syndax Pharmaceuticals Inc?
The ticker symbol of Syndax Pharmaceuticals Inc is SNDX.
What is the 52-week high of Syndax Pharmaceuticals Inc?
The 52-week high of Syndax Pharmaceuticals Inc is 25.59.
What is the 52-week low of Syndax Pharmaceuticals Inc?
The 52-week low of Syndax Pharmaceuticals Inc is 9.29.
What is the market capitalization of Syndax Pharmaceuticals Inc?
The market capitalization of Syndax Pharmaceuticals Inc is 836.74M.
Is Syndax Pharmaceuticals Inc (SNDX) currently rated as Buy, Hold, or Sell?
According to analysts, Syndax Pharmaceuticals Inc (SNDX) has an overall rating of Buy, with a price target of 38.73.
What is the Earnings Per Share (EPS TTM) of Syndax Pharmaceuticals Inc (SNDX)?
The Earnings Per Share (EPS TTM) of Syndax Pharmaceuticals Inc (SNDX) is -2.79.